The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).
 
Angela DeMichele
Honoraria - Pfizer
Research Funding - Bayer (Inst); Calithera Biosciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Millennium (Inst); Pfizer (Inst); Veridex (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - Pfizer
 
James J. Harding
No Relationships to Disclose
 
Melinda L. Telli
Consulting or Advisory Role - Vertex
Research Funding - Abbvie (Inst); Biomarin (Inst); Calithera Biosciences (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); PharmaMar (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Biomarin; Myriad Genetics
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Rana McKay
Research Funding - Bayer; Pfizer
 
Othon Iliopoulos
No Relationships to Disclose
 
Keith W. Orford
Employment - Calithera Biosciences; GlaxoSmithKline
Stock and Other Ownership Interests - Calithera Biosciences
 
Mark K. Bennett
Employment - Calithera Biosciences
Leadership - Calithera Biosciences
Stock and Other Ownership Interests - Calithera Biosciences
 
James Walter Mier
Research Funding - X4 Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Acceleron Pharma
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Bayer; Celgene; Genentech/Roche; Novartis
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Celgene (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Genetic predictor of chemotherapy sensitivity (Inst)
 
Manish R. Patel
Honoraria - Gilead Sciences; Medivation; Taiho Pharmaceutical
Research Funding - Gilead Sciences; Medivation; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Gilead Sciences; Medivation; Taiho Pharmaceutical
 
Richard D. Carvajal
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Genentech; Iconic Therapeutics; Janssen; Merck; Novartis; Thomson Reuters
Research Funding - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Celldex; Daiichi Sankyo; Genentech; Immunocore; Incyte; Lilly; Merck; Mirati Therapeutics; Novartis; Regeneron
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
Jeffrey R. Infante
No Relationships to Disclose